Bayer/€BAYN

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Bayer

Bayer AG, operating under the ticker BAYN, is a global enterprise with core competencies in the life sciences fields of healthcare and agriculture. Founded in 1863, the company is headquartered in Leverkusen, Germany, and operates in several sectors, including Pharmaceuticals, Consumer Health, Crop Science, and Animal Health. Bayer is known for developing new molecules for use in innovative products and solutions to improve the health of humans, animals, and plants.

Ticker

€BAYN
Sector

Primary listing

XETRA

Employees

89,556

Bayer Metrics

BasicAdvanced
€27B
-
-€3.48
1.00
€0.11
0.39%

What the Analysts think about Bayer

Analyst ratings (Buy, Hold, Sell) for Bayer stock.

Bulls say / Bears say

Bayer’s first-quarter adjusted EBITDA was €4.09 billion, surpassing the market consensus of €3.75 billion. This demonstrates operational strength and robust performance from the pharmaceutical segment (Reuters).
Following a major Roundup settlement, Bayer raised its 2025 sales guidance to €46–48 billion and projected adjusted EBITDA of €9.7–10.2 billion, signaling confidence in the strength of its core business (Reuters).
The company has resolved or disqualified 131,000 out of 192,000 Roundup claims, which has significantly reduced its litigation backlog and improved risk on its balance sheet (Reuters).
Bayer added €1.2 billion to its U.S. Roundup litigation reserves and still faces around 61,000 unresolved claims, representing ongoing legal liabilities that could put pressure on its cash flows (Reuters).
The Crop Science division is reducing manufacturing and R&D activities in Germany, responding to intense price competition from low-cost Asian suppliers and tougher regulation, which could impact future revenues from agrochemicals (Reuters).
Bayer’s move to exit the U.S. seed treatment equipment business highlights strategic retrenchment in the face of weak earnings and rising costs, potentially limiting long-term exposure to the agritech service market (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.

Bayer Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Bayer Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €BAYN

Sign up or log in to buy
Capital at risk
Extended hours trading

Upcoming events

No upcoming events
FAQs